Global Non-Invasive Liquid Biopsy Market Growth (Status and Outlook) 2023-2029

Global Non-Invasive Liquid Biopsy Market Growth (Status and Outlook) 2023-2029

Non-invasive liquid biopsy is to analyze and diagnose diseases such as cancer through blood or urine and other body fluids. At present, the main application area of liquid biopsy is the blood detection of tumors, that is, the use of blood to indicate tumor development and drug resistance and other information to guide individualized and precise treatment. Compared with existing tumor detection methods, liquid biopsy is non-invasive, can be detected frequently and repeatedly, and has rapid response capabilities. It has significant advantages and has great potential for application development.
LPI (LP Information)' newest research report, the “Non-Invasive Liquid Biopsy Industry Forecast” looks at past sales and reviews total world Non-Invasive Liquid Biopsy sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-Invasive Liquid Biopsy sales for 2023 through 2029. With Non-Invasive Liquid Biopsy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Invasive Liquid Biopsy industry.
This Insight Report provides a comprehensive analysis of the global Non-Invasive Liquid Biopsy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Invasive Liquid Biopsy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Invasive Liquid Biopsy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Invasive Liquid Biopsy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Invasive Liquid Biopsy.
The global Non-Invasive Liquid Biopsy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Non-Invasive Liquid Biopsy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non-Invasive Liquid Biopsy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non-Invasive Liquid Biopsy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non-Invasive Liquid Biopsy players cover Bio-Techne, Endress+Hauser, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp and Nucleix, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Invasive Liquid Biopsy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Stool Test
Urine Test
Saliva Test
Others
Segmentation by application
Hospital
Laboratory
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bio-Techne
Endress+Hauser
Exact Sciences Corporation
Lonza Group AG
MDxHealth
Merck KGaA
MutantDx
Norgen Biotek Corp
Nucleix
Oasis Diagnostics Corporation
OraSure Technologies
PerkinElmer
Predicine
Qiagen
Thermo Fisher Scientific
Zymo Research Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.